Cantor Fitzgerald raised the firm’s price target on PTC Therapeutics to $62 from $52 and keeps an Overweight rating on the shares. Cantor doesn’t believe the market is adequately crediting some “upside levers” to the stock related to clinical stage/filed-stage programs, and is a fan of sepiapterin for phenylketonuria and is warming up more to PTC518 for Huntington’s disease, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics Faces EMA Rejection, Seeks Re-examination
- PTC Therapeutics announces CHMP maintains Translarna negative opinion
- JPMorgan smid & large cap biotech analysts hold analyst/industry conference call
- PTC Therapeutics price target raised to $32 from $25 at BofA
- PTC’s 12-month PIVOT-HD update the best-case scenario, says JPMorgan